Badania u prof. Sebastiana Grosickiego w Chorzowie
- A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone(IDd) in Relapsed and/or Refactory Multiple Myeloma (RRMM) – LINK
- A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refactory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor – LINK